Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.80 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.80 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.80 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.80 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.80 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.80 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.80 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | FABP4 | P15090 | 2/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3660066 | 1.00 | APP (0.80) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3660026 | 1.00 | APP (0.80) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3661970 | 0.96 | APP (0.74) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3657105 | 0.96 | APP (0.74) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3661660 | 0.96 | APP (0.74) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3658905 | 0.90 | APP (0.84) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3654547 | 0.90 | APP (0.84) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3654545 | 0.90 | APP (0.84) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3660255 | 0.89 | PSEN1 (1.00) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3713834 | 0.89 | PSEN1 (1.00) | APPPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217064-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-07-10 | — | — | US | claimed |
| EP-2234954-B1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS INC (US) | 2015-02-18 | — | — | EP | disclosed |
| US-20140364641-A1 | Tetrasubstituted Benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8664249-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| WO-2013106328-A1 | TETRASUBSTITUTED BENZENES FOR TREATMENT OF EARLY ONSET ALZHEIMER'S DISEASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20130165486-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8367863-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120295981-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-8217064-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| EP-2234954-A1 | TETRASUBSTITUTED BENZENES | Envivo Pharmaceuticals, Inc. (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20090299072-A1 | Tetrasubstituted Benzenes | EN VIVO PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| WO-2009086277-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364641-A1 | Tetrasubstituted Benzenes | BACE1, BACE2, PSEN1 | APP 5/4885PSEN1 3/4885PSEN2 4/4885 |
| US-20090299072-A1 | Tetrasubstituted Benzenes | BACE1, BACE2, PSEN1 | APP 5/4885PSEN1 3/4885PSEN2 4/4885 |
| US-20120295981-A1 | TETRASUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | APP 5/4885PSEN1 3/4885PSEN2 4/4885 |
| US-20130165486-A1 | TETRASUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | APP 5/4885PSEN1 3/4885PSEN2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.